Day: August 11, 2023

Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab that met the primary endpoint across three dose arms with statistical significance. The data established eblasakimab, a potential first-in-class antibody, as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation Data supports advancement of eblasakimab into Phase 3 clinical development program in 2024 Readouts from TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) Phase 2 study of eblasakimab and FAST-AA (FArudodstat STudy in Alopecia Areata) Phase 2a study of farudodstat both expected in the first quarter of 2024 Company maintains healthy operating position with $40.9 million in cash and cash equivalents as of June 30, 2023; $12.0 million upfront...

WATERTOWN, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the second quarter ended June 30, 2023 and provided business highlights. “The Acrivon team has made significant progress during the second quarter, both on the clinical and preclinical development fronts, as well as with the expansion of our board and executive leadership team with strategic additions,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon....

—Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 ——Cash Runway into Q3 2024– DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2023. “We recently achieved 50% patient enrollment and expect to complete the planned enrollment of 1,966 patients in our REASSURE trial in the first quarter of next year. We have over 140 clinical trial sites currently open to enrollment in the U.S.,” said Corey Fishman, Iterum’s Chief Executive Officer. “Top-line data is...

Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the second quarter ended June 30, 2023. Vered Caplan, CEO of Orgenesis, said, “We are pleased to report revenue of approximately $7.0 million for the second quarter of 2023, which reflects the ongoing rollout of our POCare platform. We recently rebranded the POC Services business from Morgenesis to Octomera, following an additional investment from MM OS Holdings, L.P. (“MM”), an affiliate of Metalmark Capital Partners (“Metalmark”), a leading...

EDEN PRAIRIE, MN, Aug. 11, 2023 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced its 2nd quarter 2023 results. For the three months ended June 30, 2023:Revenue for the three months ended June 30, 2023 totaled $4.7 million, an increase of 20%, as compared to $3.9 million for the same period of 2022. This growth falls within the previously provided guidance range of 15-25% for Q2 2023. Revenue for the six months ended June 30, 2023 totaled $8.5 million, an increase of 19%, as compared to $7.1 million for the same period of 2022. 49 UltraMist® systems were sold in Q2 2023, up from 28 in Q1 of this year. UltraMist® consumables revenue increased 25% to $2.8 million, versus $2.2 million for the same quarter last...

— Positive Results from Phase 2b SYMMETRY Cohort D, an expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 receptor agonist, reported during the second quarter of 2023 — — Phase 3 SYNCHRONY studies on track to begin enrolling in the second half of 2023 — — 36 Weeks Results from the Phase 2b SYMMETRY study, evaluating treatment of patients with compensated cirrhosis due to NASH, on track to be reported in the fourth quarter of this year — — $334.8 million in net proceeds raised through Akero’s ATM Facility and underwritten registered direct offering of common stock — SOUTH SAN FRANCISCO, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational...

MIAMI BEACH, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the second quarter ended June 30, 2023.Cases increased 13.4% over the prior year period to 4,186Revenue increased 12.2% over the prior year to $55.7 millionNet income of $1.8 million for the quarter compared to $0.6 million in the prior year periodDiluted income per share for the quarter of $0.03Diluted adjusted net income per share for the quarter of $0.13Cash flow from operating activities of $12.2 millionOpened second international center in London“I am pleased with our performance for the second quarter and for the first half of the year,” said Todd Magazine,...

OTTAWA, Aug. 11, 2023 (GLOBE NEWSWIRE) —  Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three and six-month periods ended June 30, 2023. All amounts are in Canadian dollars and reported under International Financial Reporting Standards (“IFRS”) unless otherwise noted. “I am pleased with our financial and operating performance for the second quarter and first half of the year,” commented Dan Goldberg, Telesat’s President and CEO. “We are on track to meet the guidance we gave at the outset of the year and, as a result of our continued disciplined execution, delivered industry-leading Adjusted EBITDA margins1, high capacity utilization, a substantial contractual backlog of $1.6 billion, and a cash balance of $1.5 billion. In addition,...